Maze Therapeutics, Inc. $MAZE is Frazier Life Sciences Management L.P.'s 8th Largest Position

Key Points

• Frazier Life Sciences Management increased its Maze Therapeutics stake by 10.2% in the second quarter, bringing its holdings to 5.03 million shares worth approximately $150.2 million, or 9.06% of MAZE.
• Analyst sentiment remains generally positive: TD Cowen upgraded the stock to “strong buy,” BTIG maintained a “buy” rating with a $46 target, and the consensus rating is “Buy” with an average price target of $66.
• Despite institutional support, MAZE faces investor concerns from insider selling and ongoing losses. Insiders sold roughly $5.7 million of shares over the past 90 days, while the company reported quarterly EPS of negative $0.76 and trades below its 50-day and 200-day moving averages.

Frazier Life Sciences Management L.P. boosted its stake in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) by 10.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,032,915 shares of the company's stock after acquiring an additional 465,641 shares during the period. Maze Therapeutics accounts for about 3.3% of Frazier Life Sciences Management L.P.'s holdings, making the stock its 8th biggest position. Frazier Life Sciences Management L.P. owned about 9.06% of Maze Therapeutics worth $150,182,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Royal Bank of Canada increased its stake in shares of Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company's stock worth $27,000 after purchasing an additional 363 shares during the last quarter. Ameritas Investment Partners Inc. lifted its stake in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock valued at $42,000 after purchasing an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Maze Therapeutics during the fourth quarter valued at $43,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Maze Therapeutics in the second quarter worth $48,000. Finally, Russell Investments Group Ltd. raised its stake in shares of Maze Therapeutics by 947.8% in the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company's stock valued at $49,000 after buying an additional 1,725 shares during the period.

Key Stories Impacting Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

Maze Therapeutics Stock Performance

Maze Therapeutics stock opened at $26.21 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. Maze Therapeutics, Inc. has a fifty-two week low of $14.27 and a fifty-two week high of $53.65. The stock has a market cap of $1.46 billion, a P/E ratio of -10.40 and a beta of 2.17. The firm's fifty day moving average price is $28.69 and its 200-day moving average price is $31.06.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). Equities research analysts forecast that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on MAZE. TD Cowen raised Maze Therapeutics to a "strong-buy" rating in a report on Monday, August 24th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Wall Street Zen downgraded shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Finally, BTIG Research restated a "buy" rating and set a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $66.00.

Insiders Place Their Bets

In other news, insider Phillips Courtney sold 2,012 shares of the business's stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total transaction of $52,332.12. Following the completion of the transaction, the insider owned 7,007 shares of the company's stock, valued at approximately $182,252.07. The trade was a 22.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jason Coloma sold 11,411 shares of the company's stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total transaction of $296,800.11. Following the completion of the transaction, the chief executive officer owned 27,362 shares in the company, valued at approximately $711,685.62. This trade represents a 29.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 209,612 shares of company stock worth $5,734,575. Insiders own 5.30% of the company's stock.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

Want to see what other hedge funds are holding MAZE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.